Leptin receptor gene polymorphism may affect subclinical atherosclerosis in patients with acromegaly by Turgut, Sebahat et al.
 
Copyright © 2016, Avicenna Journal of Medical Biotechnology. All rights reserved.                         Vol. 8, No. 3, July-September 2016 
Original Article 
145
Leptin Receptor Gene Polymorphism may Affect Subclinical Atherosclerosis in Patients 
with Acromegaly 
 
Sebahat Turgut 1, Senay Topsakal 2, Melek Tunç Ata 1, Duygu Herek 3, Fulya Akın 2, Şeyma Özkan 1,  
and Günfer Turgut 1 
 
1. Department of Physiology, Faculty of Medicine, University of Pamukkale, Denizli, Turkey 
2. Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Pamukkale,  
   Denizli, Turkey 
3. Department of Radiology, Faculty of Medicine, University of Pamukkale, Denizli, Turkey  
 
 
 
Abstract 
 
Background: Acromegaly is associated with increased morbidity and mortality relat-
ed to cardiovascular diseases. Leptin (LEP) and Leptin Receptor (LEPR) gene poly-
morphisms can increase cardiovascular risks. The aim of this study was to investigate 
association between the frequencies of LEP and LEPR gene polymorphisms and sub-
clinical atherosclerosis in acromegalic patients.  
 
Methods: Forty-four acromegalic patients and 30 controls were admitted to study. 
The polymorphisms were identified by using polymerase chain reaction from periph-
eral blood samples. The levels of systolic and diastolic blood pressure, BMI, fasting 
plasma glucose, fasting insulin, IGF-I, GH, IGFBP3, leptin, triglyceride, carotid Intima 
Media Thickness (cIMT) and HDL and LDL cholesterol concentrations were evaluated.  
 
Results: There was statistically significant difference between the LEPR genotypes of 
acromegalic patients (GG 11.4%, GA 52.3%, and AA 36.4%) and controls (GG 33.3%, 
GA 50%, and AA 16.7%) although their LEP genotype distribution was similar. In ad-
dition, the prevalence of the LEPR gene G and A alleles was significantly different be-
tween patients and controls. No significant difference was found among the G(-2548) 
A leptin genotypes of groups in terms of the clinical parameters. cIMT significantly in-
creased homozygote LEPR GG genotype group compared to AA subjects in patients. 
But the other parameters were not different between LEPR genotypes groups of pa-
tients and controls.  
 
Conclusion: It can be said that the LEPR gene polymorphism may affect cIMT in pa-
tients. The reason is that LEPR GG genotype carriers may have more risk than other 
genotypes in the development of subclinical atherosclerosis in acromegaly.  
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Introduction 
 
Acromegaly is a rare disease caused by excess se-
cretion of Growth Hormone (GH) and Insulin-like 
Growth Factor (IGF)-I from a pituitary adenoma 1. 
Acromegaly is associated with increased morbidity and 
reduced life expectancy due to cardiovascular and cere-
brovascular diseases 1,2.  
Leptin is a 16 kDa protein hormone that plays a key 
role in regulating energy intake and energy expendi-
ture, including appetite control and metabolism and is 
present in the circulation in amounts proportional to 
body fat mass. It is one of the most important adipose 
derived hormone which acts by binding and activating 
the long isoform of its receptor (LEPR-b) in the hypo- 
thalamus. Leptin Receptor (LEPR) has a defined novel  
 
 
 
 
 
 
molecular pathway for energy metabolism and regula-
tion of body weight 3. It is worth noting that the role of 
leptin is supported by the universal distribution of 
LEPR and LEPR is selectively expressed in the central 
and peripheral tissues. LEPR localizes to chromosome 
1p31 and the long form has 18 exons 4. LEPR, a single-
transmembrane-domain receptor shows structural simi-
larity to the class I cytokine receptor family 5. The most 
widely studied and most functional are the polymor-
phisms of G(-2548)A leptin and A668G (Q223R) lep-
tin receptor genes 6-9. 
Measurement of Intima Media Thickness (IMT) 
with carotid doppler Ultrasonography (USG) is a use-
ful determiner of early atherosclerosis 8-11. However, 
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ultrasonographic evaluation of carotid arteries showed 
a significant increase of IMT in patients with acromeg-
aly only in some studies 12,13. Vitale et al demonstrated 
that increased levels of GH/IGF-1 were also associated 
with IMT increment 14. Moreover, in another study, 
decreases in insulin, triglyceride (TG) and fibrinogen 
levels together with IMT were detected as a conse-
quence of inhibition of GH/IGF-1 secretion in acro-
megalic patients 12. The aim of this study was to inves-
tigate the effect of G(-2548)A leptin and A668G 
(Q223R) leptin gene polymorphisms on carotis IMT, 
plasma leptin concentrations and clinical parameters in 
acromegalic patients.  
 
Materials and Methods 
Subjects 
This study was performed on forty-four unrelated 
acromegalic patients and thirty healthy subjects. The 
diagnosis of acromegaly was established on the basis 
of criteria proposed by Freda 15. The control group 
consisted of 30 healthy age-matched subjects without 
history of chronic diseases, including cardiovascular 
disease, diabetes, etc. The study protocol was approved 
by the local Ethics Committee. The procedures were 
explained to all subjects and written informed consent 
was obtained. The study protocol conformed to the 
ethical guidelines of Declaration of Helsinki as reflect-
ed in a prior approval by the institution’s human re-
search committee.  
 
Clinical and laboratory assessment  
Height and weight were measured with participants 
wearing light clothes and no shoes, and Body Mass 
Index (BMI) was calculated [(weight (kg)/height (m)2)]. 
Systolic and diastolic blood pressures were measured 
twice in the seated position after 5 min of rest. Plasma 
total and high-density lipoprotein cholesterol, triglycer-
ides, GH, IGF-1, IGFBP3, Thyroid Stimulating Hor-
mone (TSH) and insulin levels were measured.  
Blood samples were obtained by vena-puncture be-
tween 8:00 AM and 10:00 AM after a requested 12 hr 
fast. Plasma total cholesterol, triglycerides, high densi-
ty lipoprotein (HDL), light density lipoprotein (LDL), 
TSH, GH, IGF-1, IGFP3, insulin and glucose levels 
were measured immediately after vena-puncture. The 
serum samples were frozen at -80°C to measure serum 
leptin levels. 
Serum leptin were measured by ELISA method with 
human enzyme-linked immunosorbent assay kits (Invi-
trogen Company, USA) according to the manufactur-
er’s instruction. 
The cIMT measurements were made at the follow-
up visit subsequent to when blood samples were ob-
tained. B-mode ultrasonography of the left and right 
common and internal carotid arteries was performed by 
a specially trained radiology technician. Measurements 
were made at least 15 min after waiting and lying posi-
tion. After bilateral, longitudinal and transversal exam-
ination of the carotid arteries, standardized images 
were obtained 2 times in 5 min intervals on each partic-
ipant at 2 different points; at the lateral angle of the 
carotid artery bulb and 20 mm proximal of the bifurca-
tion. The common cIMT was calculated as the mean of 
the left and right measurements and cIMT>0.8 was 
evaluated as increased thickness 16.  
 
Genetic analysis 
DNA was isolated from peripheral blood by stand-
ard phenol/chloroform extraction method. Genotyping 
for Leptin (LEP) gene and LEPR gene was performed 
by polymerase chain reaction method. PCR was per-
formed with a thermal cycle (Techne, United King-
dom). PCR was conducted in 50 µl of a reaction mix-
ture containing about 1 µg of DNA sample, 5 µl reac-
tion buffer (10) containing 160 mM (NH4)2SO4, 670 
mM TrisHCL pH=8,8 0,1% Tween-20, 5 µl dNTP (2 
mM), 3 µl MgCl2 (25 mM), 1 U of Platinum Taq-poly-
merase and 100 pmol of each of primer. The following 
primers were used for LEP (-2548) G→A gene poly-
morphism; forward 5′-TTTCCTGTAATTTTCCCGTG 
AG-3′, reverse 5′-AAAGCAAAGACAGGCATAAAA 
A-3′.  
Amplification was performed for 30 cycles, each 
cycle including denaturation, extension and annealing 
temperatures of 94C for 45 s, 60C for 30 s and 72C 
for 1 min, respectively and the final extension time and 
temperature at 72C for 10 min. The initial denatura-
tion stage was carried out at 94C for 2 min. The frag-
ments obtained were electrophoresed in a 1% agarose 
gel and visualized by ethidium bromide staining under 
Ultraviolet (UV) light. PCR products were then digest-
ed by restriction enzyme Hha I at 16C overnight. En-
zyme-digested products were separated and observed 
through a gel imaging system. 
The following primers were used for LEPR Gln223- 
Arg gene polymorphism; forward primer 5′-ACCCTTT 
AAGCTGGGTGTCCCAAATAG-3′, reverse primer 5′- 
A G C TAG CAA ATAT T TT T GTA AG CAA TT-3′. The 
PCR reaction conditions used to amplify the LEPR 
gene fragments were predenaturation at 94°C for 5 
min, followed by thirty cycles of denaturation at 94°C 
for 30 s, annealing at 58°C for 30 s, and elongation at 
72°C for 30 s. The last elongation at 72°C lasted for 10 
min. PCR products were then digested by restriction 
enzyme Msp I at 16°C overnight. Enzyme-digested 
products were separated and observed through a gel 
imaging system. 
 
Statistical analysis 
Continues variables were expressed as mean±stand-
ard deviation (SD). Mann-Whitney U test was used to 
analyze differences in continues variables between two 
genotypes. Kruskal Wallis test was used to analyze 
differences in continues variables among three geno-
types. Independent sample t test was used to analyze 
differences in continuous variables between two alleles 
groups in acromegalic patients. Chi-square test was 
used for comparison of nominal variables between 
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groups. The p<0.05 were accepted as statistically sig-
nificant. A correlation analysis was performed to inves-
tigate the association between the clinical parameters. 
All analysis was carried out using SPSS 10.0 software 
(Statistical Package for Social Sciences, SPSS Inc., IL, 
USA). Statistical significance of the observed genotype 
frequencies was evaluated according to Hardy-Wein-
berg rule compared to the expected genotype frequen-
cies. Hardy-Weinberg equilibrium was evaluated by 
the 2 test. 
 
Results 
 
There were 44 patients meeting the criteria of acro-
megaly subjects. Clinical characteristics of patients and 
healthy subjects were shown in table 1. BMI, systolic 
and diastolic blood pressures, fasting glucose and GH, 
IGF-1 and IGFBP-3 levels were significantly higher in 
acromegalic patients compared to healthy subjects. 
Total cholesterol, triglyceride, HDL, LDL and leptin 
levels were similar between patients and controls. 
Also, right and left cIMTs were similar between these 
groups.  
The frequencies of the LEP and LEPR genotype in 
control and acromegalic patients were shown in table 
2. The frequency of the genotype LEP gene in patients 
showed a significant deviation from the Hardy-Wein-
berg equilibrium but did not show anything in controls. 
Observed and expected frequencies for LEP gene were 
in Hardy-Weinberg equilibrium in both the control 
group and the patients, respectively, (χ2=11.15 p<0.05), 
(χ2=1.6 p>0.05). The distribution of LEP genotypes in 
patients and control subjects were found as follows: 2 
(4.5%) acromegalic patients had GG, 32 (72.7%) pa-
tients had G/A, 10 (22.7%) patients had AA genotypes, 
whereas in control group, 1 (3.3%) subject had GG, 15 
(50%) had G/A, and 14 (46.7%) had genotypes. Re-
garding the frequency of genotype LEP (2548) gene, 
there was no significant difference between control and 
patients (p=0.097). The G allele was encountered in 36 
(40.9%) of the patients and 17 (28.3%) of the controls. 
The A allele was seen in 52 (59.1%) of the acromegalic 
patients and 43 (71.7%) of the controls. Distribution of 
the alleles was not different between two groups (A/G 
OR=1.27; 95% CI=0.98-1.65; p=0.081). 
The frequency of the genotype LEPR gene in 
patients and control groups did not show a significant 
deviation from the Hardy-Weinberg equilibrium. Ob-
served and expected frequencies for LEPR gene were 
in Hardy-Weinberg equilibrium in both the patients 
and the controls, respectively, (χ2=0.59 p>0.05), (χ2= 
0.02 p>0.05). The distribution of the LEPR (223) geno-
type was as follows: 5 (11.4%) patients had GG, 23 
(52.3%) had GA and 16 (36.4%) had AA genotype in 
acromegalic patients and 10 (33.3%) subjects had GG, 
15 (50%) had G/A and 5 (16.7%) had AA genotype in 
control group (Table 2). The frequency of genotype 
LEPR (223) gene was significantly different between 
control and patients (p=0.000). The G allele was en-
countered in 33 (37.5%) of the patients and 35 (58.3%) 
of the controls. The A allele was seen in 55 (62.5%) of 
the acromegalic patients and 25 (41.7%) of the con-
trols. Distribution of the alleles was significantly dif-
ferent between two groups (A/G OR=0.70; 95% CI= 
0.53-0.94; p=0.010). 
The levels of systolic and diastolic blood pressure 
(SBP and DBP), BMI, Fasting Plasma Glucose (FPG), 
IGF-I, GH, IGFBP3, triglyceride, total cholesterol, 
HDL and LDL cholesterol, right and left cIMT and 
plasma leptin were compared among leptin gene geno-
type groups (GG, GA and AA) in patients and controls. 
The comparisons of characteristics among LEP gene in 
acromegalic patients and controls are shown in table 3. 
No statistically significant difference was found 
among LEPR gene genotype groups (GG, GA and 
AA), as concerning BMI, SBP, DBP, fasting plasma 
glucose, IGF-I, GH, IGFBP3, triglyceride, total choles-
Table 1. The clinical characteristics of acromegalic patients and controls 
 
 Patients (n=44) Controls (n=30) p-value 
Ages (years) 51.06±10.62 46.43±6.89 NS 
BMI (kg/m²) 29.24±4.05 25.43±3.68 0.001 
Systolic BP (mmHg)            132.86±11.77 119.33±17.00 0.001 
Diastolic BP (mmHg)          81.43±6.48 76.00±10.70 0.039 
Fasting glucose (mg/dl)       111.57±11.40 94.93±11.40 0.002 
Total cholesterol (mg/dl)    187.77±42.66 200.01±42.27 NS 
TG (mg/dl)  125.64±74.75 120.12±54.43 NS 
HDL (mg/dl)                      55.39±13.45 53.50±14.86 NS 
LDL (mg/dl)                      107.76±34.30 122.55±37.38 NS 
GH (ng/l)  1.65±1.45 0.35±0.66 0.000 
IGF-1 (ng/l)  313.62±156.13 151.39±52.04 0.000 
IGFBP3 (µg/l)  5.14±1.44 4.17±1.12 0.001 
Right cIMT (mm) 0.76±0.15 0.71±0.67 NS 
Left cIMT (mm) 0.80±0.19 0.72±0.64 NS 
Leptin (ng/ml)  9.77±5.34 7.94±4.68 NS 
 
Table 2. Distribution of LEP and LEPR gene polymorphism in control and 
acromegalic patients 
 
 
Acromegaly  
n (%) 
Control 
n (%) 
p-value 
2548 polymorphism    
 Genotypes   0.097 
 AA 10 (22.7) 14 (46.7)  
 GA 32 (72.7) 15 (50.0)  
 GG 2 (4.5) 1 (3.3)  
 Alleles   0.081 
 A 52 (59.1) 43 (71.7)  
 G 36 (40.9) 17 (28.3)  
223 polymorphism    
 Genotypes   0.035 
 AA 16 (36.4) 5 (16.7)  
 GA 23 (52.3) 15 (50.0)  
 GG 5 (11.4) 10 (33.3)  
 Alleles   0.010 
 A 55 (62.5) 25 (41.7)  
 G 33 (37.5) 35 (58.3)  
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terol, HDL and LDL cholesterol, right cIMT and plas-
ma leptin level in patients and control individuals 
(Table 4). However, left cIMT in GG group was sig-
nificantly higher than AA genotypes (p<0.05). In ad-
dition, the plasma IGF-1 level was  significantly high 
in the AA genotypes of control individuals compared 
to GA and GG genotype subjects (p<0.05) (Table 4).  
In this study, statistically significant positive correl-
ation was found between right/left cIMT and systolic 
blood pressure (p<0.05). A positive correlation was 
observed between leptin levels and cIMT, but this was 
not statistically significant. 
 
Discussion  
 
Acromegaly is characterized by an enhanced GH 
secretion. GH induces the expression and secretion of 
IGF-1 and high IGFBP3 level was reported in previous 
studies. In addition, high blood pressure and high fast-
ing glucose were reported in acromegaly patients com-
pared to healthy subjects. The results of the current 
study confirm this situation 17,18. 
In this study it was revealed that there was no statis-
tically significant difference between acromegaly and 
control group for LEP A2548G genotypes and alleles; 
however, a statistically significant difference was ob-
served between these groups for LEPR 223 genotypes 
and alleles distribution in our population. LEPR 223 
AA genotype and A allele frequency in acromegaly 
group was significantly higher than the one in control 
group. The LEP and LEPR gene polymorphisms were 
investigated for the first time in acromegalic patients. 
In addition, plasma leptin levels and carotid intima 
thickness of all subjects were determined and the rela-
tionship between these genetic and clinical parameters 
was investigated.  
Some previous studies reported that leptin levels 
were low in acromegaly compared to control groups 19-
21; however, other studies did not find any significant 
Table 3. The comparisons of characteristics among LEP gene in acromegalic patients and controls 
 
 
Patients (n=44) Controls (n=30) 
GG GA AA GG GA AA 
BMI (kg/m²) 35.15±2.19 29.08±3.66 28.35±4.57 26.40 25.62±3.17 25.15±4.38 
SBP (mmHg)  135.00±7.07 132.90±11.60 132.22±13.94 110.00 118.00±15.67 121.43±19.15 
DBP (mmHg)  85.00±7.07 82.08±5.88 78.89±7.81 80.00 74.67±11.87 77.14±9.94 
FG (mg/dl)  95.55±9.12 116.18±29.00 102.82±20.15 101.70 94.15±11.50 95.29±11.97 
TC (mg/dl)  182.15±27.08 182.35±44.91 203.46±38.36 135.00 189.28±32.46 216.15±45.96 
TG (mg/dl)  175.45±147.43 122.48±76.80 122.97±68.60 82.50 115.12±51.72 128.17±59.33 
HDL (mg/dl)  44.25±10.96 55.80±12.25 56.80±16.99 50.10 51.97±15.55 55.38±15.00 
LDL (mg/dl)  108.80±0.0 102.26±34.14 122.31±34.25 68.40 114.30±27.98 135.26±42.38 
GH (ng/l)  1.46±1.5 1.75±1.27 1.42±1.98 0.10 0.43±0.88 0.28±0.30 
IGF-1 (ng/l)  429.00±188.09 325.84±170.63 255.41±102.73 161.00 154.66±60.17 147.19±45.88 
IGFBP3 (µg/l)  6.28±0.53 4.93±1.42 5.45±1.58 3.64 4.21±1.29 4.17±0.98 
Right cIMT(mm) 0.75±0.07 0.77±0.14 0.75±0.18 0.70 0.72±0.19 0.70±0.11 
Left cIMT (mm) 0.72±0.03 0.79±0.17 0.84±0.25 0.70 0.77±0.23 0.66±0.07 
Leptin (ng/ml)  6.84±2.88 9.85±6.45 7.11±5.04 13.00 7.55±4.08 7.99±5.36 
 
Table 4. The comparisons of characteristics among LEPR gene in acromegalic patients and controls 
 
 
Patients (n=44) Controls (n=30) 
GG GA AA GG GA AA 
BMI (kg/m²) 28.00±1.62 29.60±4.91 29.19±3.20 25.86±3.17 24.71±3.57 26.74±4.41 
SBP (mmHg)  134.00±5.47 132.11±13.15 133.64±12.06 120.00±14.90 116.67±16.76 126.00±23.02 
DBP (mmHg)  82.00±4.47 79.47±7.05 84.55±5.22 77.00±9.48 73.33±11.75 82.00±8.36 
FG (mg/dl)  113.68±33.72 110.90±24.69 111.77±29.73 95.19±13.59 93.90±11.68 97.52±6.10 
TC (mg/dl)  210.12±36.16 189.96±51.50 173.81±20.43 189.13±41.06 198.31±43.27 226.88±37.40 
TG (mg/dl)  131.80±96.00 138.18±85.04 101.14±48.46 122.05±55.36 117.10±60.78 125.34±39.68 
HDL (mg/dl)  64.44±14.97 53.76±11.89 54.10±14.94 53.52±11.86 51.05±15.48 60.82±18.89 
LDL (mg/dl)  119.76±24.07 109.36±42.50 99.70±20.78 111.17±38.60 123.94±37.18 141.16±34.25 
GH (ng/l)  2.82±2.22 1.22±0.91 1.86±1.62 0.52±1.08 0.24±0.34 0.40±0.45 
IGF-1 (ng/l)  240.60±84.30 293.21±154.91 382.08±174.24 161.00 154.50±38.21 161.84±61.12 
IGFBP3 (µg/l)  4.67±0.99 4.86±1.62 5.78±1.17 4.38±0.63 4.10±1.36 3.98±1.24 
Right cIMT(mm) 0.86±0.15 0.76±0.14 0.73±0.15 0.67±0.11 0.76±0.17 0.65±0.12 
Left cIMT (mm) 0.94±0.20 a 0.80±0.20 0.74±0.13 a 0.69±0.11 0.76±0.22 0.67±0.09 
Leptin (ng/ml)  11.20±9.51 8.40±5.78 9.02±5.00 6.85±4.32 8.43±4.78 8.63±5.68 
 
a: In each line, the difference between the means with same letters are significant, p<0.05 (Mann-Whitney U test) 
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difference between patients with acromegaly and 
healthy subjects 22-24. In the current study, no signifi-
cant differences were observed between groups, such 
as the second group of the study. The difference be-
tween plasma leptin levels in these studies may be due 
to the treatment that the patients receive or do not re-
ceive. However, Ciresi et al 25 did not compare plasma 
leptin levels between patients with acromegaly and 
healthy controls, leptin levels of newly diagnosed pa-
tients with acromegaly in their study like our results. 
No significant difference in leptin levels was found 
among LEP AA, GA, GG genotypes groups both in 
patients and control subjects. Also, there was no signif-
icant difference among leptin levels of LEPR gene 223 
genotypes groups in acromegalic and healthy subjects. 
Previous studies showed a significant association of 
higher leptin levels with the leptin promoter polymor-
phism (G-2548A) 6,7,26,27 and LEPR polymorphism 
Q223R 8,9. However, Su et al 28 and Gaukrodger et al 29 
report that there is no difference in leptin levels among 
the three genotypes of LEP 2548. In addition, plasma 
leptin levels were found similar among LEPR 223 
genotypes 8,9,28. The differences between results can be 
attributed to these studies performed in different pa-
tient groups and different ethnic groups. 
In our study, cIMT did not show significant differ-
ence between patients and controls. In addition, when 
the cIMT of LEP 2548 genotype individuals was ana-
lyzed within patients and the control group, no signifi-
cant change was observed between genotype groups. 
However, when the characteristics of LEPR gene in 
patients and control group were compared, left cIMT 
significantly increased in GG genotype group vs. other 
genotype groups in acromegalic patients. Also, right 
cIMT of GG genotype subjects was greater than the 
other genotype groups in acromegalic patients, but the 
difference was not significant. The Gln223Arg geno-
type is associated with the lower binding capacity of 
leptin to the soluble form of the receptor in plasma 30. 
This situation causes abnormal receptor function and 
abnormal receptor functions lead to leptin resistance 30. 
It has been determined that this variant is correlated 
with higher BMI 31 and fat mass 30. In the current 
study, the BMI of patients was found higher than con-
trol subjects and it increased in GG genotype group vs. 
other genotypes groups in acromegalic patients. It is 
well known that high BMI and fat mass is a risk factor 
for hypertension. Increased blood pressure is a major 
risk factor for cardiovascular diseases. Increased blood 
pressure can be strongly associated with increased 
cIMT. Our findings seem to confirm this result. There 
was positive correlation between systolic blood pres-
sure and cIMT in the current study. Accordingly, it can 
be said that individuals with LEPR GG genotype gene 
have a higher risk for high blood pressure and cardio-
vascular diseases.  
One limitation of this study was related to the small 
sample size. Acromegaly is a rare disease; therefore, 
there is no chance to increase the number of patients. 
However, our study is the first one about this subject 
with patients having acromegaly in Turkish population. 
Still the findings of this study are preliminary and 
further studies should be carried out to confirm our 
results.  
 
Conclusion 
 
In conclusion, the results of the present study dem-
onstrated that acromegalic patients differ from the 
healthy subjects for LEPR 223 but not LEP -2548 
polymorphism. In this study, only cIMTs were found to 
be significantly different in LEPR 223 GG genotype 
group compared to other genotypes within acromegalic 
patients. According to our data, it can be stated that the 
LEPR 223 GG genotype carriers may have more risk 
than other genotypes carriers for the development of 
early atherosclerosis in acromegaly. In fact, it is re-
quired to have further comprehensive studies in order 
to make clear this situation in acromegalic diseases. 
 
Acknowledgement  
 
The author(s) disclosed receipt of the following fi-
nancial support for the research, authorship, and/or 
publication of this article: Foundation project: The 
research is supported by The Scientific Projects Com-
mission of the Pamukkale University (Grant number: 
2011-TPF-045). 
 
Conflict of Interest 
 
The author(s) declared no potential conflicts of in-
terest with respect to the research, authorship, and/or 
publication of this article. 
 
References 
 
1. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic 
complications of acromegaly: epidemiology, pathogene-
sis, and management. Endocr Rev 2004;25(1):102-152. 
 
2. Holdaway IM, Rajasoorya RC, Gamble GD. Factors in-
fluencing mortality in acromegaly. J Clin Endocrinol 
Metab 2004;89(2):667-674. 
 
3. Friedman JM, Halaas JL. Leptin and the regulation of 
body weight in mammals. Nature 1998;395(6704):763-
770. 
 
4. Sun Q, Cornelis MC, Kraft P, Qi L, van Dam RM, Gir-
man CJ, et al. Genome-wide association study identifies 
polymorphisms in LEPR as determinants of plasma solu-
ble leptin receptor levels. Hum Mol Genet 2010;19(9): 
1846-1855. 
 
5. Frühbeck G. Intracellular signalling pathways activated 
by leptin. Biochem J 2006;393(Pt 1):7-20. 
 
6. Constantin A, Costache G, Sima AV, Glavce CS, Vla-
dica M, Popov DL. Leptin G-2548A and leptin receptor 
Q223R gene polymorphisms are not associated with obe-
sity in Romanian subjects. Biochem Biophys Res Com-
mun 2010;391(1):282-286. 
 
15
Leptin Polymorphism and Acromegaly 
Avicenna Journal of Medical Biotechnology, Vol. 8, No. 3, July-September 2016   150 
7. Şahın S, Rüstemoğlu A, Tekcan A, Taşliyurt T, Güven 
H, Yığıt S. Investigation of associations between obesity 
and LEP G2548A and LEPR 668A/G polymorphisms in 
a Turkish population. Dis Markers 2013;35(6):673-677. 
 
8. Becer E, Mehmetçik G, Bareke H, Serakıncı N. Associa-
tion of leptin receptor gene Q223R polymorphism on li-
pid profiles in comparison study between obese and non-
obese subjects. Gene 2013;529(1):16-20. 
 
9. Mohammadzadeh G, Ghaffari MA, Bafandeh A, Hos-
seini SM. Effect of leptin receptor Q223R polymorphism 
on breast cancer risk. Iran J Basic Med Sci 2014;17(8): 
588-594. 
 
10. Mukherjee D, Yadav JS. Carotid artery intimal-medial 
thickness: indicator of atherosclerotic burden and res-
ponse to risk factor modification. Am Heart J 2002;144 
(5):753-759.  
 
11. Salonen JT, Salonen R. Ultrasound B-mode imaging in 
observational studies of atherosclerotic progression. Cir-
culation 1993;87(3 Suppl):II56-65. 
 
12. Colao A, Marzullo P, Lombardi G. Effect of a six-month 
treatment with lanreotide on cardiovascular risk factors 
and arterial intima-media thickness in patients with ac-
romegaly. Eur J Endocrinol 2002;146(3):303-309. 
 
13. Otsuki M, Kasayama S, Yamamoto H, Saito H, Sumitani 
S, Kouhara H, et al. Characterization of premature ather-
osclerosis of carotid arteries in acromegalic patients. Clin 
Endocrinol (Oxf) 2001;54(6):791-796. 
 
14. Vitale G, Pivonello R, Lombardi G, Colao A. [Cardio-
vascular complications in acromegaly]. Minerva Endo-
crinol 2004;29(3):77-88. English, Italian. 
 
15. Freda PU. Current concepts in the biochemical assess-
ment of the patient with acromegaly. Growth Horm IGF 
Res 2003;13(4):171-184. 
 
16. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amar-
enco P, Bornstein N, et al. Mannheim carotid intima-
media thickness and plaque consensus (2004-2006-
2011). An update on behalf of the advisory board of the 
3rd, 4th and 5th watching the risk symposia, at the 13th, 
15th and 20th European Stroke Conferences, Mannheim, 
Germany, 2004, Brussels, Belgium, 2006, and Hamburg, 
Germany, 2011. Cerebrovasc Dis 2012;34(4):290-296. 
 
17. Hochberg I, Tran QT, Barkan AL, Saltiel AR, Chandler 
WF, Bridges D. Gene expression signature in adipose tis-
sue of acromegaly patients. PLoS One 2015;10(6): 
e0129359. 
 
18. Gläser S, Friedrich N, Ewert R, Schäper C, Nauck M, 
Dörr M, et al. Association between serum insulin-like 
growth factor (IGF) I and IGF binding protein-3 and lung 
function. J Clin Endocrinol Metab 2009;94(7):2452-
2458. 
 
19. Seravalle G, Carzaniga C, Attanasio R, Grassi G, Lonati 
L, Facchini C, et al. Decreased adrenergic tone in acro-
megaly: evidence from direct recording of muscle sym-
pathetic nerve activity. Clin Endocrinol (Oxf) 2012;77 
(2):262-267. 
 
20. Olarescu NC, Ueland T, Lekva T, Dahl TB, Halvorsen B,  
 
 
Aukrust P, et al. Adipocytes as a source of increased cir-
culating levels of nicotinamide phosphoribosyltrans  
ferase/visfatin in active acromegaly. J Clin Endocrinol 
Metab 2012;97(4):1355-1362. 
 
21. Seravalle G, Carzaniga C, Sciortino G, Attanasio R, Fatti 
LM, Cozzi R, et al. Differential patterns of regional 
neuroadrenergic cardiovascular drive in acromegalic dis-
ease. Clin Exp Pharmacol Physiol 2013;40(5):333-337. 
 
22. Roemmler J, Otto B, Arafat AM, Bidlingmaier M, Scho-
pohl J. Influence of pegvisomant on serum ghrelin and 
leptin levels in acromegalic patients. Eur J Endocrinol 
2010;163(5):727-734. 
 
23. Gurbulak S, Yaylali GF, Yerlikaya E, Akin F, Topsakal 
S, Tanrverdi H, et al. Resistin and leptin levels in acro-
megaly: lack of correlation with echocardiographic find-
ings. J Investig Med 2013;61(3):582-585. 
 
24. Olarescu NC, Heck A, Godang K, Ueland T, Bollerslev 
J. The metabolic risk in newly diagnosed patients with 
acromegaly is related to fat distribution and circulating 
adipokines and improves after treatment. Neuroendocri-
nology 2015.  
 
25. Ciresi A, Amato MC, Pizzolanti G, Giordano Galluzzo 
C. Visceral adiposity index is associated with insulin 
sensitivity and adipocytokine levels in newly diagnosed 
acromegalic patients. J Clin Endocrinol Metab 2012;97 
(8):2907-2915. 
 
26. Le Stunff C, Le Bihan C, Schork NJ, Bougnères P. A 
common promoter variant of the leptin gene is associated 
with changes in the relationship between serum leptin 
and fat mass in obese girls. Diabetes 2000;49(12):2196-
2200. 
 
27. Görmüş U, Tımırcı Kahraman Ö, Toptaş B, İsbır T, 
Çıftçı Ç, Berkkan HH, et al. Leptin and leptin receptor 
polymorphisms are related to body mass index in a Turk-
ish population. Turk J Med Sci 2014;44(5):809-813. 
 
28. Su PH, Yang SF, Yu JS, Chen SJ, Chen JY. A polymor-
phism in the leptin receptor gene at position 223 is asso-
ciated with growth hormone replacement therapy respon-
siveness in idiopathic short stature and growth hormone 
deficiency patients. Eur J Med Genet 2012;55(12):682-
687. 
 
29. Gaukrodger N, Mayosi BM, Imrie H, Avery P, Baker M, 
Connell JM, et al. A rare variant of the leptin gene has 
large effects on blood pressure and carotid intima-medial 
thickness: a study of 1428 individuals in 248 families. J 
Med Genet 2005;42(6):474-478. 
 
30. Stefan N, Vozarova B, Del Parigi A, Ossowski V, 
Thompson DB, Hanson RL, et al. The Gln223Arg poly-
morphism of the leptin receptor in Pima Indians: influ-
ence on energy expenditure, physical activity and lipid 
metabolism. Int J Obes Relat Metab Disord 2002;26(12): 
1629-1632. 
 
31. Furusawa T, Naka I, Yamauchi T, Natsuhara K, Kimura 
R, Nakazawa M, et al. The Q223R polymorphism in 
LEPR is associated with obesity in Pacific Islanders. 
Hum Genet 2010;127(3):287-294. 
Copyright of Avicenna Journal of Medical Biotechnology is the property of Avicenna
Research Institute and its content may not be copied or emailed to multiple sites or posted to a
listserv without the copyright holder's express written permission. However, users may print,
download, or email articles for individual use.
